adakitug
adakitug: 6 clinical trials tracked.
adakitug evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about adakitug, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 1 study sponsors
Clinical Trial Registry Records (6)
Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Primary endpoint: Rate of Dose Limiting Toxicities (DLT)
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Cancer Patients Undergoing Surgery
Primary endpoint: Safety of neoadjuvant Nivolumab in combination with HuMax
Tisch Cancer Institute - BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (Anti-IL-8) for NSCLC or HCC
Primary endpoint: Major Pathologic Response (MPR)
A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) - Part 1
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)
Primary endpoint: Incidence of adverse events during the treatment and follow-up (safety)
A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
Primary endpoint: IL17A expression